CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 206 enrolled
Drug / intervention
Poractant alfa, 200 mg/kg +2 moredrug
Likely dose
Poractant alfa, 200 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02482766
NCT02482766N/ACompleted

Efficacy of a New Technique -"IN-REC-SUR-E"- in Preterm Neonates With Respiratory Distress Syndrome During Non Invasive Ventilation: a Randomized Controlled Trial

Catholic University of the Sacred Heart·interventional·Posted Jun 26, 2015·Updated Feb 15, 2019

In Brief

A clinical study evaluating Poractant alfa, 200 mg/kg, Ventilator for High-frequency Oscillatory Ventilation (HFOV), and 1 other intervention for Respiratory Distress Syndrome and Hyaline Membrane Disease. Completed, enrolled 206 participants across 33 sites.

Detailed Summary

The primary hypothesis of this study is reduction in need of mechanical ventilation in the first 72 hours of life (excluding the transient tracheal intubation performed for surfactant administration and the mechanical ventilation for lung recruitment) in spontaneously breathing infants born at 24+0-27+6 weeks' gestation and failing nCPAP during the first 24 hours of life who received an HFOV recruitment maneuver (IN-REC-SUR-E) compared to no recruitment maneuver (IN-SUR-E) just prior to surfactant administration followed by prompt extubation.

Study Details

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 26, 2015
Enrollment StartNov 1, 2015
Primary CompletionSep 1, 2018
Study CompletionSep 30, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.0 years ago

Interventions

Poractant alfa, 200 mg/kgdrug

Endotracheal Surfactant administration

Ventilator for High-frequency Oscillatory Ventilation (HFOV)device

This device will be used to perform an HFOV recruitment maneuver before surfactant administration

Nasal Continuous Positive Airway Pressure (nCPAP)device

After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)